Evidence map›Paper›PMID 25414797›Full record

ArticleJournal of addiction research & therapy2014

Comparison of Caffeine and d-amphetamine in Cocaine-Dependent Subjects: Differential Outcomes on Subjective and Cardiovascular Effects, Reward Learning, and Salivary Paraxanthine.

Scott D Lane, Charles E Green, Joy M Schmitz, Nuvan Rathnayaka, Wendy B Fang, Sergi Ferré, F Gerard Moeller

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in Journal of addiction research & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00733993 (Experiment 1), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00733993 phase1 / phase2completednot on this map

Experiment 1: Adenosine Receptor A2A Antagonists and Cocaine Dependence

TypeinterventionalSponsorVirginia Commonwealth UniversityRan2008 to 2011Enrolled23ConditionsCocaine DependenceArmsCaffeine 150 MG, Placebo, Amphetamine, Caffeine 300 MG
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Effect of amphetamines on blood pressure.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Agonist Medications for the Treatment of Cocaine Use Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Scott D LaneCenter for Neurobehavioral Research on Addictions, Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center - Houston, Houston, TX USA.
Charles E GreenCenter for Neurobehavioral Research on Addictions, Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center - Houston, Houston, TX USA.
Joy M SchmitzCenter for Neurobehavioral Research on Addictions, Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center - Houston, Houston, TX USA.
Nuvan RathnayakaCenter for Neurobehavioral Research on Addictions, Department of Psychiatry & Behavioral Sciences, University of Texas Health Science Center - Houston, Houston, TX USA.
Wendy B FangCenter for Human Toxicology, University of Utah, Salt Lake City, UT, USA.
Sergi FerréIntegrative Neurobiology, Intramural Research Program, National Institute on Drug Abuse, Baltimore, MD, USA.
F Gerard MoellerDivision on Addictions, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA.
The University of Texas Health Science Center at Houston · US

Funding

Translational MR Imaging in Cocaine Pharmacotherapy DevelopmentP50DA009262 · NIDA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GREEN, CHARLES EDWARD · 1994 to 2014
$26.9M
NIDA NIH HHS P50 DA009262
6 · The paper itself

Abstract

Due to indirect modulation of dopamine transmission, adenosine receptor antagonists may be useful in either treating cocaine use or improving disrupted cognitive-behavioral functions associated with chronic cocaine use. To compare and contrast the stimulant effects of adenosine antagonism to direct dopamine stimulation, we administered 150 mg and 300 mg caffeine, 20 mg amphetamine, and placebo to cocaine-dependent vs. healthy control subjects, matched on moderate caffeine use. Data were obtained on measures of cardiovascular effects, subjective drug effects (ARCI, VAS, DEQ), and a probabilistic reward-learning task sensitive to dopamine modulation. Levels of salivary caffeine and the primary caffeine metabolite paraxanthine were obtained on placebo and caffeine dosing days. Cardiovascular results revealed main effects of dose for diastolic blood pressure and heart rate; follow up tests showed that controls were most sensitive to 300 mg caffeine and 20 mg amphetamine; cocaine-dependent subjects were sensitive only to 300 mg caffeine. Subjective effects results revealed dose × time and dose × group interactions on the ARCI A, ARCI LSD, and VAS 'elated' scales; follow up tests did not show systematic differences between groups with regard to caffeine or d-amphetamine. Large between-group differences in salivary paraxanthine (but not salivary caffeine) levels were obtained under both caffeine doses. The cocaine-dependent group expressed significantly higher paraxanthine levels than controls under 150 mg and 3-4 fold greater levels under 300 mg at 90 min and 150 min post caffeine dose. However, these differences also covaried with cigarette smoking status (not balanced between groups), and nicotine smoking is known to alter caffeine/paraxanthine metabolism via cytochrome P450 enzymes. These preliminary data raise the possibility that adenosine antagonists may affect cocaine-dependent and non-dependent subjects differently. In conjunction with previous preclinical and human studies, the data suggest that adenosine modulating drugs may have value in the treatment of stimulant use disorders.

Indexed as

Adenosine A1/A2 receptorCaffeineCardiovascular effectsCocaine dependenced-amphetamineHumanParaxanthineReward learningSubjective effects

Identifiers

PMID25414797
PMCPMC4235768
OpenAlexW2125271762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.